期刊
MINI-REVIEWS IN MEDICINAL CHEMISTRY
卷 21, 期 19, 页码 3062-3072出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389557521666210805110920
关键词
Alzheimer's disease; therapeutic vaccine; amyloid; tau; immunotherapy; targe drugs
资金
- Science and Technology Support Projects in Biomedicine Field of Shanghai Science and Technology Commission [19441907500]
- Science and Technology Action Innovation program by Science and Technology Commission of Shanghai [17411950104]
- Medical Innovation Projects of Second Military Medical University military [2017JS07]
- Characteristic Services of Veteran Cadres Memory Disorders Diagnosis and Treatment in Changzheng hospital [2020CZWJFW12]
- National Natural Science Foundation of China [82072051, 81771964]
- Basic Scientific Research Operating Expenses of Provincial Institutions of Higher Learning in Heilongjiang Province in 2020 [2020-KYywFMy-0003]
Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss and social interaction difficulties, currently lacking effective drugs for treatment.
Alzheimer's disease (AD), one of the progressive neurodegenerative disorders, is characterized by clinical features such as memory loss, acquired skill loss, apraxia, and interpersonal and social communication disorders. The AD hallmarks at the neuropathological level include intracellular neurofibrillary tangles constituted by the hyperphosphorylated tau protein as well as the senile extracellular plaques dominated by the amyloid-beta (A beta) deposits. At present, AD treatment that mainly targeted towards improving symptoms and effective drugs to delay or stop disease progression is lacking. Vaccines and antibody-based therapies are a type of natural, synthetic, and gene recombinant biological product that treat or prevent disease progression by stimulating specific or non-specific immune responses. Compared with traditional targeted drugs, vaccines and antibodybased therapies have better safety and effectiveness and can even maintain the expression and stability of A beta and Tau proteins in patients for a long time. Logically, vaccines and antibody-based therapies are somewhat different from traditional drugs because these drugs can achieve the therapeutic effect of AD by activating immune cells and regulating the immune system of patients themselves, thereby clearing disease-related proteins and long-term survival. Complete cure is also observed in some patients after receiving the immunotherapy. Currently available vaccines and antibody-based therapies mainly target A beta and phosphorylated tau proteins. There are 44 vaccines and antibodybased therapies for AD, among which nine drugs are discontinued, three drugs are inactive, eleven drugs are in clinical phase 1, twelve drugs are in clinical phase 2, and seven drugs are in clinical phase 3. Currently, no vaccines and antibody-based therapies have been approved for AD treatment. In this paper, we review and analyse the research progress of vaccines and antibody-based therapies that are used to treat AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据